Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2022-10-03 Board/Management Inform…
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 3, 2022, reporting the election of a new director, Craig B. Thompson, M.D., to the board of Regeneron Pharmaceuticals, Inc. It details the appointment and compensation arrangements for the new director. The key section is Item 5.02, which pertains to changes in directors or certain officers. There is no financial data or report attached; the document is an announcement of a board/management change. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3790 characters, which is short and consistent with an announcement rather than a full report.
2022-10-03 English
Regulatory Filings 2022
Regulatory Filings Classification · 60% confidence The provided document text appears to be heavily encoded or corrupted, containing no readable or meaningful financial, regulatory, or corporate information. There are no identifiable keywords, regulatory references, fiscal period dates, or document titles that would allow classification into any specific filing category. The text does not contain any clear financial statements, management commentary, announcements, or other typical filing content. Given the lack of discernible content, the document cannot be classified as a substantive report or announcement. According to the fallback rule, such documents should be classified as Regulatory Filings (RNS). The confidence is moderate due to the inability to extract meaningful information but the clear absence of any other category indicators.
2022-09-21 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-13 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-12 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-12 English
PRIMARY DOCUMENT
Director's Dealing
2022-09-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.